<DOC>
	<DOCNO>NCT01835093</DOCNO>
	<brief_summary>Accumulating evidence suggest role G protein-coupled inwardly-rectifying potassium ( GIRK ) channel pathology excitement nerve , medicine action ( like Tipepidine Hibenzate ) expect new curative medicine Attention Deficit / Hyperactivity Disorder ( AD/HD ) . The purpose research confirm effect carry additional dosage Tipepidine Hibenzate AD/HD patient . If suggestion obtain research effect AD/HD Tipepidine Hibenzate , contribute development medical treatment AD/HD .</brief_summary>
	<brief_title>An Open Study Tipepidine Hibenzate Patients With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>[ Inclusion Criteria ] 1 . AttentionDeficit/Hyperactivity Disorder ( AD/HD ) DSMIV TR criterion . 2 . Patients treated Atomoxetine , Methylphenidate , atypical antipsychotic drug ( risperidone , olanzapine , quetiapine , perospirone , aripiprazole , blonanserin , paliperidone ) treat . 3 . Patients stable 4weeks medication . [ Exclusion Criteria ] 1 . Patients previous hypersensitivity Tipepidine Hibenzate . 2 . Patients treat typical antipsychotic selective norepinephrine reuptake inhibitor ( NRI ) except atomoxetine stimulant except methylphenidate . 3 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>